Altana announced semi-annual results showing sales up 3.1% to 1.7 billion euros and Ebitda increasing by 14.4% to 332 million euros. The company remains committed to innovation, reinvesting seven percent of revenue into R&D. Its business strength is supported by a balanced global distribution across the Americas, Europe, and Asia.

Following positive Phase-3 study results for its personalized cancer vaccine, Moderna's stock rose nearly 130%. The vaccine, "Intismeran autogene," combined with Keytruda significantly reduced recurrence risk in malignant melanoma patients, signaling major growth potential for the company.

Hansa Rostock successfully reduced its debt to Obotritia Capital KGaA by 9.5 million Euros through a combination of an eight million Euro payment and a 1.5 million Euro debt waiver. The club owner confirmed that the remaining outstanding balance is scheduled for full repayment by 2030.

Gabriel Felbermayr warns of a global debt crisis for sovereign states, driven by rising global yields linked to Middle East instability. He criticizes central bank interventions as inflationary measures and points to the vulnerability of the USA amidst high national debt.

Altana announced positive half-year results, showing revenue growth of 3.1% to 1.7 billion euros and an EBITDA increase of 14.4%. The company continues to strongly focus on innovation by investing seven percent of its revenue in R&D, maintaining a global balance across the Americas, Europe, and Asia.

The Bundesbank revised its German economic growth forecast downward, citing weak export demand and high industrial energy costs.